Contineum Therapeutics, Inc.
CTNM
$4.95
$0.337.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -285.99% | -254.34% | -- | -- | -- |
| Total Depreciation and Amortization | 32.31% | -7.95% | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 250.31% | 300.17% | -- | -- | -- |
| Change in Net Operating Assets | 620.90% | -118.58% | -- | -- | -- |
| Cash from Operations | -269.75% | -228.38% | -- | -- | -- |
| Capital Expenditure | -24.15% | -525.71% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -6.28% | 27.15% | -- | -- | -- |
| Cash from Investing | -6.36% | 26.35% | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 68,454.09% | 99,357.80% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 94.03% | 93.37% | -- | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -35.55% | 92.08% | -- | -- | -- |